1. Circulation. 2016 Sep 20;134(12):847-57. doi:
10.1161/CIRCULATIONAHA.116.022922.  Epub 2016 Aug 30.

Adherence to Antihypertensive Treatment and the Blood Pressure-Lowering Effects 
of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial.

Azizi M(1), Pereira H(2), Hamdidouche I(2), Gosse P(2), Monge M(2), Bobrie G(2), 
Delsart P(2), Mounier-Véhier C(2), Courand PY(2), Lantelme P(2), Denolle T(2), 
Dourmap-Collas C(2), Girerd X(2), Michel Halimi J(2), Zannad F(2), Ormezzano 
O(2), Vaïsse B(2), Herpin D(2), Ribstein J(2), Chamontin B(2), Mourad JJ(2), 
Ferrari E(2), Plouin PF(2), Jullien V(2), Sapoval M(2), Chatellier G(2); 
DENERHTN Investigators.

Collaborators: Amar L, Lorthioir A, Pagny JY, Claisse G, Midulla M, Dauphin R, 
Fauvel JP, Rouvière O, Cremer A, Grenier N, Lebras Y, Trillaud H, Heautot JF, 
Larralde A, Paillard F, Cluzel P, Rosenbaum D, Alison D, Claudon M, Popovic B, 
Rossignol P, Baguet JP, Thony F, Bartoli JM, Drouineau J, Sosner P, Tasu JP, 
Velasco S, Vernhet-Kovacsik H, Bouhanick B, Rousseau H, Le Jeune S, Lopez-Sublet 
M, Bellmann L, Esnault V, Baguet JP, Vernhet-Kovacsik H, Durand-Zaleski I, 
Beregi Chair JP, Lièvre M, Persu A.

Author information:
(1)From Paris-Descartes University, France (M.A., P.-F.P., V.J., M.S., G.C.); 
Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, 
Hypertension Unit, France (M.A., G.B., P.-F.P.); INSERM, CIC1418, Paris, France 
(M.A., H.P., G.C.); Assistance Publique-Hôpitaux de Paris, Hôpital Européen 
Georges Pompidou, Clinical Research Unit, France (H.P., G.C.); Assistance 
Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Department of 
Pharmacology, France (I.H., V.J.); Centre Hospitalier Universitaire de Bordeaux, 
Hôpital Saint André, Cardiology/Hypertension Department, France (P.G.); Institut 
Mutualiste Montsouris, Paris, France (M.M.); Centre Hospitalier Régional 
Universitaire de Lille, Hôpital Cardiologique, Médecine Vasculaire et HTA, 
France (P.D., C.M.-V.); Hôpital Croix-Rousse, Cardiology Department, European 
Society of Hypertension Excellence Centre, Hospices Civils de Lyon, and 
Université de Lyon, CREATIS UMR5220; INSERM U1044; INSA-Lyon; Université Claude 
Bernard Lyon 1; Hospices Civils de Lyon, France (P.-Y.C., P.L.); Hôpital Arthur 
Gardiner, Centre d'excellence en HTA Rennes-Dinard, France (T.D.); Centre 
Hospitalier Universitaire de Rennes, Service de Cardiologie et Maladies 
Vasculaires, France (C.D.-C.); Assistance Publique-Hôpitaux de Paris, Hôpital de 
la Pitié Salpétrière, France (X.G.); Hôpital Bretonneau, Tours, France (J.M.H.); 
CHU Nancy-Brabois, Nancy, France (F.Z.); CHU de Grenoble, France (O.O.); CHU de 
la Timone, Marseille, France (B.V.); CHU de Poitiers, Cardiologie, France 
(D.H.); CHRU Montpellier, France (J.R.); CHU Rangueil, Toulouse, France (B.C.); 
Hôpital Avicenne, Bobigny, France (J.-J.M.); Hôpital Pasteur, Nice, France 
(E.F.); INSERM, UMR 1129, Paris, France (V.J.); Assistance Publique-Hôpitaux de 
Paris, Hôpital Européen Georges Pompidou, Vascular and Oncological 
Interventional Radiology Department, France (M.S.). michel.azizi@aphp.fr.
(2)From Paris-Descartes University, France (M.A., P.-F.P., V.J., M.S., G.C.); 
Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, 
Hypertension Unit, France (M.A., G.B., P.-F.P.); INSERM, CIC1418, Paris, France 
(M.A., H.P., G.C.); Assistance Publique-Hôpitaux de Paris, Hôpital Européen 
Georges Pompidou, Clinical Research Unit, France (H.P., G.C.); Assistance 
Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Department of 
Pharmacology, France (I.H., V.J.); Centre Hospitalier Universitaire de Bordeaux, 
Hôpital Saint André, Cardiology/Hypertension Department, France (P.G.); Institut 
Mutualiste Montsouris, Paris, France (M.M.); Centre Hospitalier Régional 
Universitaire de Lille, Hôpital Cardiologique, Médecine Vasculaire et HTA, 
France (P.D., C.M.-V.); Hôpital Croix-Rousse, Cardiology Department, European 
Society of Hypertension Excellence Centre, Hospices Civils de Lyon, and 
Université de Lyon, CREATIS UMR5220; INSERM U1044; INSA-Lyon; Université Claude 
Bernard Lyon 1; Hospices Civils de Lyon, France (P.-Y.C., P.L.); Hôpital Arthur 
Gardiner, Centre d'excellence en HTA Rennes-Dinard, France (T.D.); Centre 
Hospitalier Universitaire de Rennes, Service de Cardiologie et Maladies 
Vasculaires, France (C.D.-C.); Assistance Publique-Hôpitaux de Paris, Hôpital de 
la Pitié Salpétrière, France (X.G.); Hôpital Bretonneau, Tours, France (J.M.H.); 
CHU Nancy-Brabois, Nancy, France (F.Z.); CHU de Grenoble, France (O.O.); CHU de 
la Timone, Marseille, France (B.V.); CHU de Poitiers, Cardiologie, France 
(D.H.); CHRU Montpellier, France (J.R.); CHU Rangueil, Toulouse, France (B.C.); 
Hôpital Avicenne, Bobigny, France (J.-J.M.); Hôpital Pasteur, Nice, France 
(E.F.); INSERM, UMR 1129, Paris, France (V.J.); Assistance Publique-Hôpitaux de 
Paris, Hôpital Européen Georges Pompidou, Vascular and Oncological 
Interventional Radiology Department, France (M.S.).

Comment in
    Circulation. 2016 Sep 20;134(12):858-60.

BACKGROUND: The DENERHTN trial (Renal Denervation for Hypertension) confirmed 
the blood pressure-lowering efficacy of renal denervation added to a 
standardized stepped-care antihypertensive treatment for resistant hypertension 
at 6 months. We report the influence of adherence to antihypertensive treatment 
on blood pressure control.
METHODS: One hundred six patients with hypertension resistant to 4 weeks of 
treatment with indapamide 1.5 mg/d, ramipril 10 mg/d (or irbesartan 300 mg/d), 
and amlodipine 10 mg/d were randomly assigned to renal denervation plus 
standardized stepped-care antihypertensive treatment, or the same 
antihypertensive treatment alone. For standardized stepped-care antihypertensive 
treatment, spironolactone 25 mg/d, bisoprolol 10 mg/d, prazosin 5 mg/d, and 
rilmenidine 1 mg/d were sequentially added at monthly visits if home blood 
pressure was ≥135/85 mm Hg after randomization. We assessed adherence to 
antihypertensive treatment at 6 months by drug screening in urine/plasma samples 
from 85 patients.
RESULTS: The numbers of fully adherent (20/40 versus 21/45), partially 
nonadherent (13/40 versus 20/45), or completely nonadherent patients (7/40 
versus 4/45) to antihypertensive treatment were not different in the renal 
denervation and the control groups, respectively (P=0.3605). The difference in 
the change in daytime ambulatory systolic blood pressure from baseline to 6 
months between the 2 groups was -6.7 mm Hg (P=0.0461) in fully adherent and -7.8 
mm Hg (P=0.0996) in nonadherent (partially nonadherent plus completely 
nonadherent) patients. The between-patient variability of daytime ambulatory 
systolic blood pressure was greater for nonadherent than for fully adherent 
patients.
CONCLUSIONS: In the DENERHTN trial, the prevalence of nonadherence to 
antihypertensive drugs at 6 months was high (≈50%) but not different in the 
renal denervation and control groups. Regardless of adherence to treatment, 
renal denervation plus standardized stepped-care antihypertensive treatment 
resulted in a greater decrease in blood pressure than standardized stepped-care 
antihypertensive treatment alone.
CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique 
identifier: NCT01570777.

© 2016 American Heart Association, Inc.

DOI: 10.1161/CIRCULATIONAHA.116.022922
PMID: 27576780 [Indexed for MEDLINE]
